NEWS

NEWS

TropIQ presents at the Drug Design and Development seminar in Munich

TropIQ will contribute two oral presentations to the 2022 Drug Design and Development Seminar of the German Society for Parasitology: Analysis of tick regurgitation following mechanical, cryogenic and chemical removal ...
Read more
/ News

MMV, PPSC and TropIQ present a webinar on state of the art in malaria phenotypic screening

On June 22nd at 4 pm CET, the Medicines for Malaria Venture, the Pivot Park Screening Centre and TropIQ will present a webinar on their collaborative work in malaria phenotypic ...
Read more
/ News

Antimalarial MMV’183 is a clinical development candidate

TropIQ's parasitology platform drove the optimisation of pantothenamide compounds that generated MMV'183: a candidate for further clinical development with a new mode of action for treatment of malaria and blocking transmission ...
Read more
/ News

TropIQ publishes innovative mosquito barcoding technology

We present a barcoding strategy that enables phenotypic screens of blood-feeding insects against small molecules in microtiter plate-based arrays and apply this to discovery of novel systemic insecticides and compounds ...
Read more
/ News

TropIQ awarded large research grant to uncover new mosquito repellents.

Together with researchers from the University of Washington, TropIQ was awarded 1.3 million USD from the Bill & Melinda Gates Foundation to find new mosquito repellents and thus aid the ...
Read more
/ News

MalDA prioritises malaria drug targets with TropIQ’s input

The Malaria Drug Accelerator (MalDA), of which TropIQ is part of, has put together a prioritisation of molecular targets against the malaria parasite Plasmodium falciparum. This publication further advocates target ...
Read more
/ News

Our team aids the discovery of a new anti-malarial scaffold.

Due to the continuing rise of resistances against commonly used medication, new anit-malarials are needed to combat the disease. This publication suggests Quinazolinone-2-carboxamide derivatives as a novel malaria drug. read ...
Read more
/ News

Review of MalDA’s scientific achievements just released

TropQI has been a part of The Malaria Drug Accelerator (MalDA) since 2018. This consortium consists of 17 research laboratories funded by the Bill and Melinda Gates foundation to advance ...
Read more
/ News

Our liver stage platform supports life cycle profiling for new anti-malarial.

In the battle against malaria new drugs are needed. This publication identified 1-(pyridine-4-yl)pyrrolidine-2-one derivates as a novel, dual stage active (asexual blood stages and liver stage), anti-malaria. read more here ...
Read more
/ News

TropIQ assists in life cycle profiling of genetically modified chimeric Plasmodium parasite.

To broaden the protective spectrum of a potential whole parasite vaccine against malaria, a chimeric P. falciparum parasite expressing P. falciparum and P. vivax circumsporozoite protein (csp) was generated. This ...
Read more
/ News

TropIQ Digitalises Its Discovery Platform with CDD Vault

CDD Vault will enable TropIQ Health Sciences to share research results with partners in real time Nijmegen and San Francisco October 8, 2020 TropIQ Health Sciences, a  biotechnology ...
Read more
/ News

TropIQ contributes to research on malaria vaccine

Production of the primary vaccine candidate Plasmodium falciparum circumsporozoite protein (PfCSP) has proven difficult. This publication for the first time presents a method to produce a soluble, full-length PfCSP which ...
Read more
/ News

Dr. Sheshachalam is joining TropIQ

Dr. Sheshachalam has joined the team as a Scientist. He is an experienced cell biologist with a broad expertise in immunology, molecular biology and drug discovery. He obtained his PhD ...
Read more
/ News

TropIQ CEO Koen Dechering gives radio interview on the new malaria drug candidate

Dutch national radio (BNR) has conducted an interview with TropIQ's CEO Koen Dechering on the recently published novel malaria drug candidate (see publication here). Listen to the interview here (in ...
Read more
/ News

TropIQ-led collaboration develops novel malaria candidate drug

A molecule once designed to cure the skin disease psoriasis appears to be particularly effective against malaria. The antimalarial properties were revealed thanks to one researcher’s inspired hunch when the ...
Read more
/ News

TropIQ gains new Assistant Scientist

Mrs. De Bruijn is joining the Team as a Assistant Scientist with a wealth of experience in laboratory techniques in the fields of immunology, cell biology and molecular biology. She ...
Read more
/ News

TropIQ gains Business Administrator

Mrs. Bijsterveld is joining TropIQ as a Business Administrator with a strong background in financial management in various different fields of work. In her previous affiliations she acquired higher lever ...
Read more
/ News

TropIQ at the ICM Weekend School

TropIQ organised a science workshop at the IMC Weekend School. This is a supplementary school on Sundays for children (aged 10-14) from underprivileged neighbourhoods. Through a three-year course, professionals (volunteers) ...
Read more
/ News

New master student at TropIQ

Ms. Sascha Bezemer is joining the team as our new intern. She is a biology master student with specialisation in health and disease. She is enrolled at Wageningen University and ...
Read more
/ News

TropIQ’s CSO, Robert Sauerwein knighted

Robert Sauerwein, CSO of TropIQ, receives a royal decoration for his pioneering work in malaria vaccinology and drug discovery. He receives the distinction of Knight in the Order of the ...
Read more
/ News